Open Access85. Final 5-Year Safety and Efficacy Results of a Phase 3, Randomized, Placebo-Controlled Trial of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy
Author(s) -
Josef S Smolen,
Jonathan Kay,
Robert Landewé,
Eric K. Matteson,
Norman Gaylis,
J. Wollenhaupt,
Frederick T. Murphy,
Chenglong Han,
T. Gathany,
Stephen Xu,
Yiying Zhou,
Elizabeth C. Hsia,
Mittie K. Doyle
Publication year - 2014
Publication title -
rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.957
H-Index - 173
eISSN - 1462-0332
pISSN - 1462-0324
DOI - 10.1093/rheumatology/keu101.006
Subject(s) - golimumab , medicine , rheumatoid arthritis , placebo , randomized controlled trial , tumor necrosis factor α , tumor necrosis factor alpha , physical therapy , surgery , adalimumab , alternative medicine , pathology